Feasibility and activity of two vinflunine (VFL)-based combinations as first-line chemotherapy (CT) in CDDP-unfit patients (pts) with advanced urothelial carcinoma (UC): VFL-gemcitabine (GEM) or VFL-CBDCA in a randomized international phase II trial (JASINT).
Maria De Santis
Consultant or Advisory Role - Celgene; Pierre Fabre Medicament (U); Shionogi
Honoraria - Pierre Fabre Medicament
Research Funding - Pierre Fabre Medicament
Pawel J. Wiechno
No relevant relationships to disclose
Christel Lucas
Employment or Leadership Position - Pierre Fabre Medicament
Research Funding - Pierre Fabre Medicament
Wu-Chou Su
No relevant relationships to disclose
Laurence Albiges
No relevant relationships to disclose
Chia-Chi Lin
Honoraria - Pierre Fabre Medicament
Joaquim Bellmunt
Consultant or Advisory Role - Pierre Fabre Medicament (U)
Elzbieta Senkus-Konefka
Honoraria - Pierre Fabre Medicament
Aude Flechon
Research Funding - Pierre Fabre Medicament
Loic Mourey
No relevant relationships to disclose
Andrea Necchi
No relevant relationships to disclose
Wolfgang C. Loidl
Consultant or Advisory Role - Pierre Fabre Medicament
Maryse Morand
Employment or Leadership Position - Pierre Fabre Medicament
Jean-Philippe Burillon
Employment or Leadership Position - Pierre Fabre Medicament
Ronan Fougeray
Employment or Leadership Position - Pierre Fabre Medicament
Stephane Culine
Consultant or Advisory Role - Pierre Fabre Medicament (U)
Honoraria - Pierre Fabre Medicament
Research Funding - Pierre Fabre Medicament